Why the study?
Autoimmunity contributes to heart muscle diseases, but the functional features of human cardiac autoimmunity remain undefined due to the challenge of studying in situ immune responses.
Do c-Met+ T cells define cardiac autoimmunity and does c-Met inhibition halt disease development in experimental autoimmune myocarditis?
Do c-Met+ T cells define cardiac autoimmunity and does c-Met inhibition halt disease development in experimental autoimmune myocarditis?
Circulating c-Met+ T cells identify cardiac autoimmunity and represent a potential diagnostic biomarker and therapeutic target for inflammatory cardiomyopathies.
Answers are grounded in this paper and cite their sources.
May aid noninvasive monitoring of cardiac autoimmunity; leaves open therapeutic targeting of c-Met+ T cells pending trials.
Background: Autoimmunity is increasingly recognized as a key contributing factor in heart muscle diseases. The functional features of cardiac autoimmunity in humans remain undefined because of the challenge of studying immune responses in situ. We previously described a subset of c-mesenchymal epithelial transition factor (c-Met)–expressing (c-Met + ) memory T lymphocytes that preferentially migrate to cardiac tissue in mice and humans. Methods: In-depth phenotyping of peripheral blood T cells, including c-Met + T cells, was undertaken in groups of patients with inflammatory and noninflammatory cardiomyopathies, patients with noncardiac autoimmunity, and healthy controls. Validation studies were carried out using human cardiac tissue and in an experimental model of cardiac inflammation. Results: We show that c-Met + T cells are selectively increased in the circulation and in the myocardium of patients with inflammatory cardiomyopathies. The phenotype and function of c-Met + T cells are distinct from those of c-Met–negative (c-Met − ) T cells, including preferential proliferation to cardiac myosin and coproduction of multiple cytokines (interleukin-4, interleukin-17, and interleukin-22). Furthermore, circulating c-Met + T cell subpopulations in different heart muscle diseases identify distinct and overlapping mechanisms of heart inflammation. In experimental autoimmune myocarditis, elevations in autoantigen-specific c-Met + T cells in peripheral blood mark the loss of immune tolerance to the heart. Disease development can be halted by pharmacologic c-Met inhibition, indicating a causative role for c-Met + T cells. Conclusions: Our study demonstrates that the detection of circulating c-Met + T cells may have use in the diagnosis and monitoring of adaptive cardiac inflammation and definition of new targets for therapeutic intervention when cardiac autoimmunity causes or contributes to progressive cardiac injury.
No takes yet. Share an insight, caveat, or question.
Fanti et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: